Response Pharmaceuticals

🗓 Founded 2022👥 4 employees💰 Last funded Nov 2024
Biotechnology Research🌐 responsepharmaceuticals.com
Website LinkedIn
Response Pharmaceuticals is developing its lead asset, RDX-002, a first-in-class weight management and cardiometabolic health drug with confirmed efficacy and safety in >550 subjects. All programs are in Phase 2 clinical development. Our initial focus is on helping underserved patient populations taking antipsychotic medications for disabling mental illnesses to combat weight gain and metabolic dysregulation associated with these treatments. Antipsychotic-induced weight gain (AIWG) is a drug-induced epidemic within the already vulnerable population of patients with severe mental illness, and is contributing to a growing mortality gap between people with mental illness and the general population. Additionally, RDX-002 is being evaluated in other settings in which clinically significant weight gain and/or adverse metabolic changes are prevalent.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2022
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in Response Pharmaceuticals?
Response Pharmaceuticals has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Response Pharmaceuticals last raise funding?
The most recent investment in Response Pharmaceuticals recorded on gritt.io was in November 2024.
When was Response Pharmaceuticals founded?
Response Pharmaceuticals was founded in 2022.
What industry is Response Pharmaceuticals in?
Response Pharmaceuticals operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.